Poverty Barrier Blocks Access to New HIV Drug

Last month, Kenya commenced distribution of lenacapavir, a drug considered a significant advancement in the fight against HIV. The government aims to reduce new infections by 2030, but communities like Kibera, a large informal settlement in Nairobi, are not prioritized in the initial phase. HIV prevalence in Nairobi's informal settlements is twice that of non-slum urban areas, yet Kibera's main health facility is excluded from the first 21,000 doses.

Community leaders express frustration over the lack of explanation for this exclusion. For Kibera residents, traveling to designated facilities, located 1.5 to 3.5 miles away, incurs costs between 220 and 380 Kenyan shillings (£1.30 to £2.20) one-way. This expense is prohibitive for those living on less than £1.50 daily, forcing difficult choices between transport and food.

Concerns are also growing about the drug's future affordability. While currently free, lenacapavir could eventually cost around 7,800 Kenyan shillings (£45) annually, even with subsidies. International agreements aim to reduce this to approximately £30 per patient by 2027 with generic versions, but current supply remains limited.

This situation highlights broader worries that scientific breakthroughs are outstripping delivery systems for equitable access. Health authorities state this is an initial phase, but structural challenges like transport costs and clinic travel time have historically hindered HIV treatment retention in Kenya. A community-based approach, utilizing existing local networks, is proposed as a more effective model for ensuring patient follow-up and adherence.